Abstracts Archive - Page 1994 of 2425 - ACR Meeting Abstracts

Abstract Number: 865 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events Prior to or Early after Diagnosis of SLE
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson², Dominique Ibanez³ and Systemic Lupus International Collaborating Clinics (SLICC)⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Division of Rheumatology, University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON, Canada
Background/Purpose: A large multicenter multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. Previous studies have shown a history of…
Abstract Number: 866 • 2014 ACR/ARHP Annual Meeting
Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe⁴, David Albert⁵, Judith A. James⁶ and Joan T. Merrill³, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵AliveCor, Inc., San Francisco, CA, ⁶Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heart rate variability (HRV) is a marker of vagus nerve activity and can be easily obtained with minimal technical expertise in the outpatient setting,…
Abstract Number: 864 • 2014 ACR/ARHP Annual Meeting
Association of Coronary Artery Calcification with Brown and White Pericardial Adipose Tissue in SLE
Kelly J. Shields, Medicine, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA
Background/Purpose Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). We have shown that clinically CVD-free women with SLE have…
Abstract Number: 863 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome in Young Premenopausal Female Lupus Patients Is Mainly Influenced By Therapies
Luciana Muniz¹, Rosa M.R. Pereira², Thiago Silva³, Eloisa Bonfá⁴ and Eduardo Ferreira Borba¹, ¹Rheumatology Division, University of São Paulo, São Paulo, Brazil, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: A high prevalence of metabolic syndrome (MetS) has been observed in Systemic Lupus Erythematosus (SLE) patients, but there are scarce data about the main…
Abstract Number: 861 • 2014 ACR/ARHP Annual Meeting
Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus
Clayton Sontheimer¹ and Keith B. Elkon², ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions often contain plasmacytoid dendritic cells (pDC). The mechanisms…
Abstract Number: 862 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Changes in Subclinical Atherosclerosis As Measured By Carotid Intima Media Thickness (IMT) and Plaque over 5 Years in Women with Systemic Lupus Erythematosus (SLE)
Apinya Lertratanakul¹, Peggy W. Wu², Alan Dyer¹, William Pearce¹, Emma Barinas-Mitchell³, Trina Thompson³ and Rosalind Ramsey-Goldman⁴, ¹Northwestern University, Chicago, IL, ²Rheumatology, Northwestern University, Chicago, IL, ³Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL
Background/Purpose: Women with SLE have increased rates of subclinical atherosclerosis. We have investigated which risk factors may be related to the increase in subclinical atherosclerosis,…
Abstract Number: 860 • 2014 ACR/ARHP Annual Meeting
Inhibition of G Protein βγ Signaling Inhibits Nephritis in Lupus Prone Mice
Teresa Owen¹, Javier Rangel-Moreno², Jesi To³, Bruce Goldman⁴, Alan Smrcka³ and Jennifer H. Anolik⁵, ¹Rheumatology, University of Rochester, Rochester, NY, ²Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ³Pharmacology & Physiology, University of Rochester, Rochester, NY, ⁴Pathology, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose G protein-coupled receptors (GPCRs), including chemokine receptors on leukocytes, signal through G protein Gβγ subunits. An important target of Gβγ is phosphoinositide 3 kinase γ…
Abstract Number: 879 • 2014 ACR/ARHP Annual Meeting
Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up
Eleonora Zaccara¹, Domenico Sambataro², Wanda Maglione¹, Gianluca Sambataro¹, Francesco Onida³, Claudio Annaloro³, Giorgia Saporiti³, Elena Tagliaferri³, Agostino Cortelezzi³, Rosaria Giordano⁴, Claudio Vitali⁵ and Nicoletta Del Papa², ¹U.O.C. Day Hospital Reumatologia, Osp. G. Pini, Milano, Italy, ²Rheumatology Unit, Istituto G.Pini, Milan, Italy, ³Hematology-BMT Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, ⁴Franco Calori Cell Factory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, ⁵Sezione Reumatologia, Istituto San Giuseppe, Lecco, Italy
Background/Purpose In the recent years, autologous haematopoietic stem cell transplantation (AHSCT) has been shown to represent an effective therapeutic option for patients (pts) suffering from…
Abstract Number: 851 • 2014 ACR/ARHP Annual Meeting
A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Propensity Score-Matched Cohort Study
Jakub Zavada¹, Michal Uher², Katarina Sisol³, Sarka Forejtova⁴, Katerina Jarosova⁵, Herman F. Mann⁶, Jiri Vencovsky⁷ and Karel Pavelka⁸, ¹Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁷Institute of Rheumatology and Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁸Institute of Rheumatology, Praha, Czech Republic
Background/Purpose: To compare effectiveness, safety and costs of standard versus individually tailored reduced doses of anti-TNF drugs in patients with Ankylosing Spondylitis (AS) after achieving…
Abstract Number: 850 • 2014 ACR/ARHP Annual Meeting
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Jacqueline E. Paramarta¹, Maureen C. Turina¹, Tanja F. Heijda², Iris C. Blijdorp³, Troy Noordenbos¹, Nataliya Yeremenko² and Dominique L. Baeten⁴, ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
René Cordtz¹, Lene Mellemkjær², Bente Glintborg¹, Merete Lund Hetland³ and Lene Dreyer¹, ¹Department of Rheumatology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ³DANBIO Registry and Department of Rheumatology., Copenhagen University Hospital Glostrup. On behalf of all departments of Rheumatology in Denmark., Glostrup, Denmark
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…
Abstract Number: 847 • 2014 ACR/ARHP Annual Meeting
Safety of TNF Inhibitor Therapy in Patients Who Have Had a Prior Malignancy
Seung-Hyeon Bae, Doo-Ho Lim, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose A few is known about the effects of biologic therapy in patients with a history of a solid cancer. According to the 2012 updated…
Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Pauline Raaschou¹, Julia F Simard², Charlotte Asker-Hagelberg³, Johan Askling⁴ and the ARTIS Study group⁵, ¹Karolinska Institutet, Stockholm, Sweden, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden, ⁴Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…
Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Layla Saliba¹, Guillaume Moulis², Malak Aboutaam³, Grégory Pugnet², Vanessa Rousseau¹, Leila Chebane¹, Nadine Petitpain⁴, Bernadette Baldin⁵, Jean-Louis Montastruc¹ and Haleh Bagheri¹, ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, ²Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, ⁴Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, ⁵Nice University Hospital, Pharmacovigilance Regional Center, Nice, France
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].